P/E ratio for Mallinckrodt Pharmaceuticals (MNK)
P/E ratio as of May 2024 (TTM): -0.0028
According to Mallinckrodt Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.00280971.
P/E ratio history for Mallinckrodt Pharmaceuticals from 2022 to 2022
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.7 | -382,103.84% | 🇺🇸 USA |
 General Electric GE | 18.7 | -664,880.35% | 🇺🇸 USA |
 Zogenix ZGNX | -6.56 | 233,208.06% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -6.99 | 248,680.12% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.